Universitaetsklinikum Duesseldorf — Biomedical Watch V2

Essais liés2clinical trials

VilleDüsseldorflocalisation

PaysGermanylocalisation

SourcelocaleCSV/MySQL

Informations

centre

Synchronisé depuis ClinicalTrials.gov — NCT05748171

Molécule	Indication / population	Phase	NCT	Titre	Statut
Inotuzumab ozogamicin	Cancer	Phase 2	NCT05748171	A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL	RECRUITING
Ocrelizumab	SEP	Phase 3	NCT05269004	OLERO — A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis	ACTIVE_NOT_RECRUITING